WallStSmart
CING

Cingulate Inc

NASDAQ: CING · HEALTHCARE · BIOTECHNOLOGY

$5.25
-5.06% today

Updated 2026-10-28

Market cap
$63.40M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.51
Dividend yield
—
52W range
$3 – $12
Volume
0.1M

Cingulate Inc (CING) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2019202020212022202320242025
Operating cash flow$-9.53M$-6.81M$-10.43M$-15.88M$-15.03M$-18.45M$-17.25M
Capital expenditures$1.02M$402096.00$814736.00$153420.00$224096.00$211800.00$162138.00
Depreciation———————
Stock-based comp—$0.00$12.78M$800796.00$812670.00$995484.00$1.52M
Free cash flow$-10.55M$-7.21M$-11.25M$-16.04M$-15.26M$-18.66M$-17.41M
Investing cash flow———————
Financing cash flow———————
Dividends paid———————
Share repurchases———————
Debt repayment———————
Net change in cash———————

Frequently asked questions

How much free cash flow does CING generate?

CING produced $-17.41M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CING's balance sheet healthy?

CING holds $10.95M in cash and equivalents against $1.15M in long-term debt, on $2.51M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.